…share. EFTA01466004 Iclusig is now indicated for those with the T315I mutation and in salvage therapy, albeit with a caveat. The new label allows Iclusig to be used as a third-line agent after Gleevec and a second - generation TKI such as Tasigna and Sprycel. However, as 60% of patients in the United States and 50% in Europe are initiating therapy with Tasigna or Sprycel, Iclusig could still potentially be used as second-line therapy in these patients after they…